The US Food and Drug Administration has approved Johnson & Johnson’s oral pill for psoriasis, the company said on Wednesday. The decision paves the way for a more convenient treatment option for patients with the chronic autoimmune condition. Psoriasis causes itchy, scaly, and inflamed patches of skin. The drug will help J&J expand into the psoriasis market as its blockbuster injectable Stelara faces increasing competition from low-cost copycat drugs.
The health regulator approved the drug for moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age and older. Patients must weigh at least 40 kilograms to qualify for treatment. The company did not immediately respond to Reuters’ requests for comment on pricing and availability. The drug, branded as Icotyde, will compete with Bristol Myers Squibb’s Sotyktu and AbbVie’s Skyrizi in the growing oral psoriasis market.
Blockbuster Potential Identified
Wall Street analysts have said J&J’s Icotyde has “blockbuster potential” as a safe and effective oral treatment. The once-daily medication could capture significant market share, analysts predict. The drug has shown superior skin clearance compared to Bristol’s Sotyktu in two late-stage head-to-head trials. These results position the J&J oral psoriasis pill strongly against existing competitors.
Patients have been looking for complete skin clearance, a favorable safety profile, and the simplicity of a once-a-day pill, David Lee, J&J’s global head of immunology, told Reuters ahead of the decision. “We see Icotyde as becoming the first-line systemic therapy for psoriasis patients,” said Lee. This ambitious goal would require displacing established treatments that physicians currently prescribe routinely.
Mechanism of Action
J&J’s oral pill, like AbbVie’s Skyrizi and J&J’s own Tremfya, is designed to block a protein involved in inflammatory responses. The target, IL-23, plays a key role in the immune system dysfunction that drives psoriasis. By inhibiting this protein, the drug aims to interrupt the inflammatory cascade that produces skin lesions.
The oral drug was developed in partnership with Protagonist Therapeutics, a biotechnology company specializing in peptide-based therapies. This collaboration combined J&J’s development expertise with Protagonist’s novel compound discovery capabilities. The partnership structure allows both companies to share in the drug’s commercial success.
Expanding Beyond Psoriasis
J&J is also studying the drug, chemically known as icotrokinra, for several other inflammatory conditions. These include ulcerative colitis, psoriatic arthritis, and Crohn’s disease. Successful expansion into these indications would significantly increase the drug’s market potential. Each condition affects millions of patients worldwide and represents substantial commercial opportunity.
Ulcerative colitis and Crohn’s disease, both forms of inflammatory bowel disease, affect approximately three million Americans. Psoriatic arthritis develops in up to 30 percent of psoriasis patients. The drug’s mechanism targeting IL-23 suggests potential efficacy across this range of inflammatory conditions. Clinical trials in these additional indications are ongoing.
Market Context and Competition
The psoriasis treatment market has evolved significantly in recent years. Biologic injectables dominated for years due to their efficacy. However, patient preference for oral medications has driven development of pills like Icotyde and Sotyktu. Convenience and avoidance of injections appeal to many patients, particularly those with mild to moderate disease.
AbbVie’s Skyrizi, an injectable biologic, has become a market leader in psoriasis. Its efficacy and safety profile set a high bar for new entrants. However, Skyrizi requires injection, giving oral alternatives a potential convenience advantage. Bristol’s Sotyktu, approved earlier, established the oral segment but left room for improvement in efficacy.
The J&J oral psoriasis pill enters this competitive landscape with efficacy data suggesting superiority over the leading oral alternative. If confirmed in real-world use, this advantage could drive rapid adoption. Physicians typically prefer the most effective option when safety profiles remain comparable. However, pricing decisions will also influence which drugs payers cover and which patients receive.
Patient Impact
For patients with moderate-to-severe plaque psoriasis, new treatment options expand choices. Many patients cycle through multiple therapies before finding one that works for them. Some respond better to oral medications than injectables, while others prefer the convenience of pills regardless of efficacy.
Complete skin clearance represents the ultimate goal for both patients and physicians. Visible skin lesions cause not only physical discomfort but also psychological distress and social stigma. Treatments that achieve clear skin can dramatically improve quality of life. The J&J oral psoriasis pill’s performance in trials suggests it can help more patients reach this goal.
Pediatric approval also addresses an important unmet need. Adolescents with psoriasis face unique challenges, including bullying and self-esteem issues during formative years. Having an oral option approved for patients as young as 12 provides additional treatment flexibility for this vulnerable population.
